论文部分内容阅读
血小板激活因子(PAF)是一种具有生物活性的磷脂。它由包括神经元细胞在内的各种细胞所产生。具有神经调节功能。PAF 被 PAF 乙酰水解酶灭活。PAF 乙酰水解酶有细胞内外两种类型。该酶在血浆与低密度脂蛋白(LDL)和高密度脂蛋白(HDL)结合。PAF 在缺血性脑损害中起重要作用,PAF 的失活可能是缺血性中风后的病理生理状态的一种决定因素。由此,本文作者测定了缺血性中风病人血浆 LDL 和HDL 中 PAF 乙酰水解酶的活性。病人和方法选33例缺血性中风病人,男17、女16例,平均年龄65±9.9岁,来使用过对脂质、脂蛋白代谢或血小板功能有影响的药物。另选择31名健康对照者(男16、女15名,平均年龄64±8.7岁)。采用超速离心法从血浆中分离出LDL 和 HDL,测定每个部分的 PAF 乙酰水解酶
Platelet-activating factor (PAF) is a bioactive phospholipid. It is produced by a variety of cells, including neuronal cells. With neuromodulation. PAF is inactivated by PAF acetylhydrolase. PAF acetylhydrolase has both intracellular and extracellular types. This enzyme binds to low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma. PAF plays an important role in ischemic brain damage and inactivation of PAF may be a determinant of the pathophysiological state following ischemic stroke. As a result, the authors measured PAF acetylhydrolase activity in plasma LDL and HDL in patients with ischemic stroke. Patients and Methods 33 patients with ischemic stroke, 17 males and 16 females, with an average age of 65 ± 9.9 years, were enrolled in this study. Drugs that had an effect on lipid, lipoprotein metabolism, or platelet function were used. Another 31 healthy controls (16 men and 15 women, mean age 64 ± 8.7 years) were selected. LDL and HDL were separated from plasma using ultracentrifugation and each fraction of PAF acetylhydrolase